DNA Methylation Biomarker Discovery for Aging-Related Cardiovascular Diseases
Technology Platforms & Expertise
Online Inquiry

DNA Methylation Biomarker Discovery for Aging-Related Cardiovascular Diseases


Many age-related chronic diseases are associated with changes in DNA methylation, including cardiovascular disease. Cardiovascular diseases are a group of diseases that affect the structure and function of the heart or blood vessels, including atherosclerosis, heart failure, myocardial infarction, and hypertension. In studies on cardiovascular disease risk, DNA methylation levels have been found to correlate with their predisposing factors. Therefore, the discovery and identification of DNA methylation at specific CpG sites may be a source for the development of biomarkers for cardiovascular diseases. With a unique technology platform, CD BioSciences can provide DNA methylation biomarker discovery services for aging-related cardiovascular diseases.

DNA Methylation Biomarker Discovery for Aging-Related Cardiovascular Diseases

Our DNA Methylation Biomarker Discovery Services for Aging-Related Cardiovascular Diseases

DNA Methylation Biomarker Discovery for Aging-Related Cardiovascular Diseases

  • Sample processing. We receive blood or other forms of samples and collect and organize information about the sample's physical characteristics, aging disease characteristics, etc. Biological materials obtained from patients with aging-related cardiovascular diseases undergo stringent processing to extract high-quality DNA suitable for comprehensive DNA methylation analysis.
  • DNA methylation analysis. Using advanced DNA methylation analysis approaches, we investigate the DNA methylation patterns associated with aging-related cardiovascular diseases. We identify relevant CpG loci based on data analysis and perform validation and subsequent association studies. We evaluate DNA methylation data through computer-based statistical analysis, correction of data bias, and association model construction and testing.
  • Identification and validation of DNA methylation biomarkers. We use advanced technologies to conduct DNA methylation profiling to discern differential methylation patterns specific to aging-related cardiovascular disease samples. Through stringent data preprocessing and statistical analysis, we identify and validate regional loci exhibiting high specificity and potential clinical utility.

Deliverables of Our DNA Methylation Biomarker Discovery Services

  • Executive summary
    We provide an executive summary of the entire research protocol, including a description of all materials used in the study and detailed descriptions of the methodology, which can be used for your paper publication.
  • Complete dataset
    Our dataset comprises raw DNA methylation data, aging-related cardiovascular sample parameters, post-quality control data, statistical analysis graphs, and various parameters for constructing analytical models.
  • Explanatory analysis
    Our interpretive analysis presents the discovery of specific DNA methylation sites, validation results, and association analysis between aging, DNA methylation, and cardiovascular diseases.

Our Advantages

  • We can analyze a variety of body fluids, tissues, cells, and other samples that are relatively easy to obtain.
  • We provide comprehensive DNA methylation data by various approaches, such as bisulfite conversion-based methods, targeted next-generation sequencing, and high-throughput DNA methylation arrays, offering greater potential for biomarker discovery.
  • Our report not only analyzes the global association between DNA methylation and aging-related cardiovascular diseases but also includes risk factor studies.

CD BioSciences is committed to being a professional partner you can trust to provide you with first-class technical services to accelerate your DNA methylation biomarker discovery projects and maximize your project applications. If you have any needs, you can contact us and we will solve your doubts and provide detailed information.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.